Abstract
The high-grade neuroendocrine carcinoma (HGNEC) of the lung, small cell lung cancer (SCLC), and large cell neuroendocrine carcinoma (LCNEC), remain fatal due to lack of new therapeutic options and prognostic milestone to guide efficient treatment. We aim to explore the prognostic value of genetic aberration and PARP expression of HGNEC and to establish a novel prognostic model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
